$FENC
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Healthcare
Sector
Biotechnology
Industry
Jeffrey S. Hackman
CEO
32
Employees
$5.77
Current Price
$241.89M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $164,568.68 | 20,428 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 3 | $242,939.88 | 30,740 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | Raykov Rosty Director | Sale | 10,079 | $8.36 | $84,260.44 | View Details |
| Feb 2, 2026 | Raykov Rosty Director | Sale | 10,349 | $7.76 | $80,308.24 | View Details |
| Jan 2, 2026 | Raykov Rosty Director | Sale | 10,312 | $7.60 | $78,371.20 | View Details |
22 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated$0.04
ActualN/A
Revenue
Estimated$14.67M
ActualN/A
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated$0.04
ActualN/A
Revenue
Estimated$14.73M
ActualN/A
EPS
Estimated$0.03
ActualN/A
Revenue
Estimated$14.73M
ActualN/A
EPS
Estimated$0.03
ActualN/A
Revenue
Estimated$14.73M
ActualN/A
EPS
Estimated$0.03
ActualN/A
Revenue
Estimated$14.73M
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history